Patents by Inventor Gerardo Enrique Guillen Nieto
Gerardo Enrique Guillen Nieto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090274718Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: June 12, 2009Publication date: November 5, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20090221512Abstract: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.Type: ApplicationFiled: February 23, 2007Publication date: September 3, 2009Inventors: Jorge Berlanga Acosta, Danay Cibrian Vera, Diana Garcia Del Barco Herrera, Gerardo Enrique Guillen Nieto, Jose Suarez Alba, Ernesto Lopez Mola, Manuel Selman-Housein Sosa, Mariela Vazquez Castillo
-
Publication number: 20090221508Abstract: The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKKYKGKFW, showing aminoacids substitutions, these peptides unable to bind to the lipopolysaccharide and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.Type: ApplicationFiled: February 23, 2007Publication date: September 3, 2009Inventors: Maribel Guerra Vallespi, Isis del Carmen Torrrens Madrazo, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Gerardo Enrique Guillen Nieto, Boris Ernesto Acevedo Castro, Raimundo Ubieta Gomez
-
Patent number: 7566457Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonspecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: February 13, 2007Date of Patent: July 28, 2009Assignee: Centro de Ingeniera Genetica y BiotecnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20090104223Abstract: The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.Type: ApplicationFiled: October 10, 2007Publication date: April 23, 2009Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
-
Publication number: 20080311157Abstract: This invention describe the a pharmaceutical compound having the capsid protein of Dengue virus capable of induce in the receptor a protective immune response before the viral challenge without inducing the Ab-dependent enhancement phenomenon.Type: ApplicationFiled: September 18, 2006Publication date: December 18, 2008Inventors: Laura Lazo Vazquez, Lisset Hermida Cruz, Carlos Lopez Abarrategui, Beatriz de la Caridad Sierra Vazquez, Susana Vazquez Ramundo, Iris Valdez Prado, Gerardo Enrique Guillen Nieto, Maria Guadalupe GuzmanTirado, Aida Zulueta Morales
-
Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
Patent number: 7361638Abstract: This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods.Type: GrantFiled: December 17, 2001Date of Patent: April 22, 2008Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Jorge Berlanga Acosta, Gerardo Enrique Guillen Nieto, Diana Garcia Del Barco Herrera, Julio Raul Fernandez Masso, Mario Pablo Estrada Garcia, Isabel Guillen Perez, Jose Suarez Alba, Rebeca Martinez Rodriguez -
Patent number: 7279164Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: July 12, 2002Date of Patent: October 9, 2007Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20040234951Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: June 7, 2004Publication date: November 25, 2004Inventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20040202676Abstract: The present invention is related to the method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.Type: ApplicationFiled: March 1, 2004Publication date: October 14, 2004Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
-
Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
Publication number: 20030186865Abstract: This invention relates to human medicine, and particularly with a pharmaceutical combination made up with Epidermal Growth Factor (EGF) and a Growth Hormone secretagogue hexapeptide (GHRP); being useful to prevent tissue damages due to blood flow suppression as to enhance tissue repair following ischaemic damages. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is useful to promote cellular survival when tissues or organs are exposed to prolonged ischaemic periods.Type: ApplicationFiled: April 22, 2003Publication date: October 2, 2003Inventors: Jorge Berlanga Acosta, Gerardo Enrique Guillen Nieto, Diana Garcia Del Barco, Julio Raul Fernandez Masso, Mario Pablo Estrada Garcia, Isabel Guillen Perez, Jose Suarez Alba, Rebecca Martinez Rodriguez -
Patent number: 6383488Abstract: The present invention relates to five synthetic peptides of pre-M/M protein of Dengue-2 virus, corresponding to amino acid sequences 3-31, 45-67, 57-92, 69-93 and 103-124. The anti-peptide immune response was evaluated in mice. Recombinant fusion proteins were also obtained, including regions of pre-M/M protein. The presence of B cell epitopes in both mice and humans was demonstrated in the pre-M/M protein peptides. Peptides 3-31 and 103-124 elicited neutralizing antibodies against the four serotypes of Dengue virus. Virus-specific proliferative responses were demonstrated in mice immunized with non-conjugated peptides 3-31 and 57-92. Mice immunized with conjugated peptides 3-31, 57-92, and 69-93 were protected when they were challenged with Dengue-2 virus. Thus, the presence of sequential epitopes in Pre-M/M protein of Dengue-2 virus was demonstrated, as well as their relevance in the immune response against this flavivirus.Type: GrantFiled: October 14, 1999Date of Patent: May 7, 2002Assignees: Centro de Ingeniera Genetic Y Biotechnologies (CIGB), Instituto de Medicina Tropical “Pedro Kouri”Inventors: Susana Vazquez Ramudo, Guadalupe Guzman Tirado, Gerardo Enrique Guillen Nieto, Orlando Luis Pardo Lazo, Glay Chinea Santiago, Ana Beatriz Perez Diaz, Maritza Pupo Antunez, Rosmari Rodriguez Roche, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Gabriel Padron Palomares, Maylin Alvarez Vera, Luis Morier Diaz, Omaida Perez Insuita, Jose Luis Pelegrino Martinez De La Cotera
-
Patent number: 6358933Abstract: The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.Type: GrantFiled: May 5, 2000Date of Patent: March 19, 2002Assignee: Centro de Ingenieria Genetica Y BiotechologiaInventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Maria de Jesus Leal Angulo, Dagmara Pichardo Diaz, Enrique Iglesias Perez, Antonieta Herrera Buch, Belquis Sandez Oquendo, Alexis Musacchio Lasa, Diogenes Quitana Vazquez, Lissere Crombet Menedez
-
Patent number: 6355414Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.Type: GrantFiled: January 6, 2000Date of Patent: March 12, 2002Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Maria de Jesus Leal Angulo, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Gloria Veliz Rios, Dagmara Pichardo Diaz, Antonieta Herrera Buch, Enrique Iglesias Perez, Luis Javier Cruz Ricondo, Tania Carmenate Portilla, Cirse Mesa Pardillo, Maydel Hechavarria Gay, Maylin Diaz Martinez, Juan Joel Madrazo Piñol